Navigation Links
WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release
Date:2/8/2013

SHANGHAI, Feb. 8, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the fourth quarter of 2012 after the New York Stock Exchange closes on Thursday, March 7, 2013 (which will be Friday morning, March 8, 2013 Shanghai time). The earnings release will be available on the investor relations section of the Company's website at http://www.wuxiapptec.com/.

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 9:00 pm (Beijing/Shanghai/Hong Kong) on Friday, March 8, 2013, to discuss the fourth-quarter 2012 financial results and recent business activities. The conference call may be accessed by calling: United States:

1-866-519-4004 China (Landline):

800-819-0121 China (Mobile):

400-620-8038Hong Kong:

800-930-346United Kingdom:

0-808-234-6646International:

+65-6723-9381 Conference ID: 99349171A telephone replay will be available two hours after the call's completion at: United States:

1-855-452-5696 China (Landline):

800-870-0205China (Mobile):

400-120-0932Hong Kong:

800-963-117United Kingdom:

0-808-234-0072International:

+61-2-8199-0299 Conference ID:

99349171A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at http://www.wuxiapptec.com/.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech (Cayman) Inc.
Tel: +1-201-585-2048
Email: Ron_Aldridge@wuxiapptec.com
Web: http://www.wuxiapptec.com


'/>"/>
SOURCE Wuxi PharmaTech Co. Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
2. Industry Leading Pharmaceutical News Website in-Pharmatechnologist.com Refocused and Relaunched
3. WuXi PharmaTech Announces First-Quarter 2012 Results
4. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
5. WuXi PharmaTech Announces Second-Quarter 2012 Results
6. WuXi PharmaTech Receives GLP Certificate from SFDA for Suzhou Toxicology Facility
7. WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
8. WuXi PharmaTech and Open Monoclonal Technology Announce OmniRat(TM) Antibody Collaboration
9. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
10. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
11. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016 According to the latest ... Market Study on Multiplex Detection Immunoassay: North America to ... global multiplex detection immunoassay market is expected to witness a CAGR ... ...      (Logo: http://photos.prnewswire.com/prnh/20161114/438683LOGO) ...
(Date:12/7/2016)... 2016 The global  blood ... of USD 3.9 billion by 2024, based on ... The growth of the market is attributed to ... advancements by the market players. Demand for blood ... donation, rising awareness about transfusion-transmitted diseases, and technological ...
(Date:12/6/2016)... 6, 2016  Alopexx Oncology, LLC announced data from ... fusion protein (immunocytokine) composed of interleukin-2 and a CD20-targeting ... on B cells as Rituxan and maintains the activities ... also involved in tumor targeting, engagement of the immune ... results of the study (abstract #95954) were presented at ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Students attending ... the unique opportunity to get hands-on experience in an emergency medical simulation, When ... experience to gain invaluable, real-life medical skills that are critical success in a ...
(Date:12/7/2016)... ... December 07, 2016 , ... Children exposed to secondhand ... at the Icahn School of Medicine at Mount Sinai has found. The study ... young children are exposed to secondhand marijuana smoke, measurable amounts of primary metabolite ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... up with a schizophrenic mother in a unique, personal perspective through animation. ... treating trauma and addictive disorders at her private psychotherapy practice. Sheri’s mother, Pearl, ...
(Date:12/7/2016)... ... December 07, 2016 , ... It is vital for any lab to secure ... data. The team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools ... need to operate in a GLP (Good Laboratory Practice) fashion. , With features designed ...
(Date:12/7/2016)... ... 2016 , ... Levels of a protein in the blood associated with heart ... in the journal Radiology. , Heart disease and brain disease exact a major burden ... aging population. Damage to both organs often occurs at a subclinical stage, or before ...
Breaking Medicine News(10 mins):